ERICA VANSANT, PH.D. Vice President

Direct: 617 425 8394

Fax: 617 425 8001

erica.vansant@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Dr. VanSant specializes in the application of economic analysis to complex litigation matters in the areas of health care, antitrust, and intellectual property (IP). Her litigation experience has included antitrust claims against an aligner and intraoral scanner manufacturer involving allegations of monopolization and anticompetitive agreements, antitrust claims against brand and generic drug manufacturers involving allegations of reverse payment settlements, pricing of generic pharmaceuticals, and IP disputes involving biologic and biosimilar pharmaceutical manufacturers. In her litigation work, Dr. VanSant has analyzed large datasets in order to estimate overcharges, ill-gotten gains, pass-through, and damages. She has assisted attorneys and academic affiliates in all phases of complex litigation, including pretrial discovery, case strategy, expert reports, deposition support, and trial preparation. Prior to joining Analysis Group, Dr. VanSant worked at an economic consulting firm.

EDUCATION

2018	Ph.D., economics, Tepper School of Business at Carnegie Mellon University
2016	M.S., economics, Tepper School of Business at Carnegie Mellon University
2009	B.A., economics (magna cum laude), The George Washington University

PROFESSIONAL EXPERIENCE

2018–Present Analysis Group, Inc.

Vice President (2024–Present)

Manager (2021–2023) Associate (2018–2020)

2009–2018 Solutions Economics, LLC

Special Consultant (2013–2018)

Consultant (2011–2013) Senior Analyst (2010–2011) Analyst (2009–2010)

SELECTED CONSULTING EXPERIENCE

Snow v. Align Technology Inc; Simon and Simon PC v. Align Technology Inc.
 US District Court, Northern District of California, San Francisco Division
 Supported experts in evaluating economic issues in antitrust actions brought by classes of purchasers of aligners alleging monopolization claims and anticompetitive agreements. The experts analyzed issues related to class certification, merits, damages, and market definition.

Confidential Pharmaceutical Antitrust Matter

US District Court, Eastern District of Pennsylvania

Supported an expert in evaluating economic issues in an alleged price-fixing matter involving generic drugs.

Value Drug Company v. Takeda Pharmaceuticals USA Inc., et al.

US District Court, Eastern District of Pennsylvania

Supported an expert in evaluating economic issues in an alleged conspiracy to delay generic entry involving a gout treatment. The expert analyzed issues related to market definition.

• Staley, et al. v. Gilead Sciences Inc., et al.

US District Court, Northern District of California, San Francisco Division

Supported an expert in evaluating economic issues in an alleged reverse payment antitrust matter involving HIV drugs. The expert analyzed issues related to class certification of the direct purchaser class.

■ Touchland Holding Corp., et al. v. Zobele Holding SpA, et al.

Chamber of Arbitration of Milan

Supported experts in evaluating economic and FDA regulatory issues in an alleged breach of contract involving a manufacturer and distributor of hand sanitizer. The experts analyzed issues related to damages and FDA regulations.

■ In re: Zetia (Ezetimibe) Antitrust Litigation

US District Court, Eastern District of Virginia

Supported an expert in evaluating economic issues in an alleged reverse payment antitrust matter involving a treatment for high cholesterol. The expert analyzed issues related to class certification of the direct purchaser class, as well as damages.

• Genentech, Inc., and City of Hope v. Amgen Inc.

US District Court, District of Delaware

Supported an academic affiliate in evaluating economic issues related to preliminary injunction, permanent injunction, commercial success, and economic damages in a matter pertaining to an IP dispute for a biologic oncology treatment.

• In re: National Prescription Opiate Litigation

US District Court, Northern District of Ohio, Eastern Division

On behalf of a national chain pharmacy, supported Professor Anupam Jena in the evaluation of issues related to the identification of suspicious orders of opiates, and harm resulting from alleged suspicious orders.

■ In re: Loestrin 24 FE Antitrust Litigation

US District Court, District of Rhode Island

Supported an expert in an alleged reverse payment settlement and an alleged anticompetitive product-switching strategy involving oral contraceptives.

■ In re: Glumetza Antitrust Litigation

US District Court, Northern District of California

Supported an expert in assessing damages related to alleged reverse payment settlements in an antitrust matter involving a direct purchaser class, as well as opt-out purchasers.

• Federal Trade Commission, et al. v. Vyera Pharmaceuticals, LLC, et al.

US District Court, Southern District of New York

Assisted an expert engaged by the defendants to address market definition and competitive effects issues, including evaluating the opposing experts' market analysis, competitive effects analysis, and proposed damages estimation method.

SELECTED PRESENTATIONS AND SPEAKING ENGAGEMENTS

Midwest Economic Association Annual Meeting (2016)

SELECTED HONORS AND AWARDS

2013–2017 William Larimer Fellowship, Carnegie Mellon University

2017 GSA/Provost Conference Funding